Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Change in the number of shares and votes in Egetis Therapeutics
Share Issue/Capital Change Classification · 91% confidence The document is a press release disclosing changes in the number of ordinary and class C shares (conversion of employee stock options) and the resulting vote counts. It is an official announcement of a capital structure change (share issue/conversion). Therefore, it fits the “Share Issue/Capital Change” category (SHA).
2026-05-29 English
Ändring av antalet aktier och röster i Egetis Therapeutics
Share Issue/Capital Change Classification · 90% confidence The document is a press release announcing a change in the number of shares and voting rights due to the exercise of staff options and conversion of C-shares into common shares. It is not a full financial report, director dealing, or dividend notice; it specifically relates to a change in share capital structure. This fits ‘Share Issue/Capital Change’ (SHA).
2026-05-29 Swedish
Ändring av antalet aktier och röster i Egetis Therapeutics
Share Issue/Capital Change Classification · 100% confidence The document is a press release dated April 30, 2026, announcing an increase in the number of shares and votes in Egetis Therapeutics due to a directed share issue. It provides specific details about the share capital increase and total shares and votes. The document is short (4075 characters) and focuses on the change in capital structure due to a share issuance. It does not contain financial statements or detailed financial analysis but is an announcement of a capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2026-04-30 English
Change in the number of shares and votes in Egetis Therapeutics
Share Issue/Capital Change Classification · 100% confidence The document is a press release dated April 30, 2026, announcing a change in the number of shares and votes in Egetis Therapeutics due to a directed issue of new ordinary shares. It provides specific details about the increase in shares, votes, and share capital. The content focuses on capital structure changes rather than financial results or management commentary. There is no indication of a full financial report or detailed financial statements. The document is relatively short (4123 characters) and is clearly an announcement of a capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2026-04-30 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Delårsrapport januari–mars 2026” and contains detailed narrative from the CEO, comprehensive financial statements for the first quarter (sales, cash flow, balance sheet metrics), tables comparing the period to prior periods, and substantive analysis of business developments. It is clearly a standalone interim (quarterly) report, not merely an announcement or presentation. Therefore, it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-04-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is clearly labeled as an “Interim report January–March 2026” and contains comprehensive quarterly financial statements, narrative from the CEO, detailed financial tables for the period, and outlook commentary. It is not merely an earnings release highlighting key metrics, nor is it an announcement of a report; it is the full interim/quarterly financial report itself. Thus, it falls under the Interim / Quarterly Report category (IR). Q1 2026
2026-04-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.